berberine has been researched along with Metabolic Syndrome in 21 studies
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks." | 9.69 | Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. ( Alvarez-Zavala, M; Andrade-Villanueva, JF; González-Hernández, LA; Martínez-Ayala, P; Méndez-Clemente, AS; Navarro-Lara, SA; Ruiz-Herrera, VV; Sánchez-Reyes, K; Toscano-Piña, M; Valle-Rodríguez, A, 2023) |
| "The aim of this study was to evaluate the efficacy and safety of berberine as an adjuvant in treating antipsychotic-associated weight gain and metabolic syndrome." | 9.51 | Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. ( Chan, M; Chen, EYH; Feng, Y; Han, F; Lai, WH; Lam, M; Lee, CK; Lee, EHM; Liu, L; Man, SC; Ng, RMK; Qin, Z; Wong, HK; Wong, TL; Zhang, ZJ, 2022) |
| "A meta-analysis of randomized controlled trials (RCTs) was conducted to systematically evaluate the effects of berberine on the inflammatory markers of metabolic syndrome (MetS) and related disorders." | 9.22 | The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials. ( Chang, F; Dai, Z; He, J; Lu, Y; Shi, P; Zhang, X, 2022) |
| "The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion." | 9.17 | Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ( Espinel-Bermúdez, MC; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA, 2013) |
| "To give an overview of the therapeutic potential of berberine as a treatment for dementia associated with diabetes." | 9.05 | Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. ( Bell, J; Bligh, A; Katsuno, T; Parkinson, J; Shinjyo, N, 2020) |
| "To elucidate the protective effect of berberine on olanzapine induced-metabolic syndrome." | 7.91 | Berberine attenuates olanzapine induced-metabolic syndrome. ( Al-Gareeb, AI; Al-Kuraishy, HM; Al-Naimi, MS; Rasheed, HA, 2019) |
| "Berberine is a natural product that shows benefits for metabolic syndrome (MS)." | 7.81 | Berberine Attenuates Vascular Remodeling and Inflammation in a Rat Model of Metabolic Syndrome. ( Gao, HQ; Ji, XP; Li, CB; Li, XX; Wang, HW; Xiao, J; Zhang, C; Zhang, XY, 2015) |
| "It was found that AUC0-t, Cmax, Vd and CL of berberine and palmatine in metabolic syndrome rats were significantly different (P<0." | 7.80 | Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats. ( Jiao, Z; Li, ZD; Liu, QF; Shi, XJ; Wang, B; Zhong, MK, 2014) |
| "Berberine is a plant alkaloid possessing scientifically determined mechanisms of the prevention of the development of atherosclerosis, type 2 diabetes, and obesity, as well as cardiovascular complications and cancer." | 6.82 | Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. ( Nowak, R; Och, A; Och, M; Podgórska, D; Podgórski, R, 2022) |
| "In this double-blind, placebo-controlled trial, adults living with HIV under virological suppression and metabolic syndrome received either berberine 500 mg TID or placebo for 20 weeks." | 5.69 | Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection. ( Alvarez-Zavala, M; Andrade-Villanueva, JF; González-Hernández, LA; Martínez-Ayala, P; Méndez-Clemente, AS; Navarro-Lara, SA; Ruiz-Herrera, VV; Sánchez-Reyes, K; Toscano-Piña, M; Valle-Rodríguez, A, 2023) |
| "The aim of this study was to evaluate the efficacy and safety of berberine as an adjuvant in treating antipsychotic-associated weight gain and metabolic syndrome." | 5.51 | Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. ( Chan, M; Chen, EYH; Feng, Y; Han, F; Lai, WH; Lam, M; Lee, CK; Lee, EHM; Liu, L; Man, SC; Ng, RMK; Qin, Z; Wong, HK; Wong, TL; Zhang, ZJ, 2022) |
| " The aim of this study was to evaluate the potential beneficial effects of Armolipid Plus (AP) (berberine 500 mg, red yest rice, monacolin K 3 mg and policosanol 10 mg) on insulin resistance, lipid profile, particularly on small and dense LDL cholesterol (sdLDL-C), representing the most atherogenic components, as well as its effects on high sensitivity C-reactive protein, a notable marker of cardiovascular risk, blood pressure and cardiac remodeling in subjects affected by MetS, with left ventricular hypertrophy." | 5.30 | Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. ( Battista, F; Bonaduce, D; Bosso, G; Brambilla, N; D'Amato, M; Fazio, V; Galletti, F; Gentile, M; Giacovelli, G; Mercurio, V; Pucci, G; Schillaci, G; Vitalini, C, 2019) |
| "A meta-analysis of randomized controlled trials (RCTs) was conducted to systematically evaluate the effects of berberine on the inflammatory markers of metabolic syndrome (MetS) and related disorders." | 5.22 | The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials. ( Chang, F; Dai, Z; He, J; Lu, Y; Shi, P; Zhang, X, 2022) |
| "The aim of this study was to evaluate the effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion." | 5.17 | Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ( Espinel-Bermúdez, MC; González-Ortiz, M; Martínez-Abundis, E; Pérez-Rubio, KG; Robles-Cervantes, JA, 2013) |
| "To give an overview of the therapeutic potential of berberine as a treatment for dementia associated with diabetes." | 5.05 | Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. ( Bell, J; Bligh, A; Katsuno, T; Parkinson, J; Shinjyo, N, 2020) |
| "To elucidate the protective effect of berberine on olanzapine induced-metabolic syndrome." | 3.91 | Berberine attenuates olanzapine induced-metabolic syndrome. ( Al-Gareeb, AI; Al-Kuraishy, HM; Al-Naimi, MS; Rasheed, HA, 2019) |
| "Berberine is a natural product that shows benefits for metabolic syndrome (MS)." | 3.81 | Berberine Attenuates Vascular Remodeling and Inflammation in a Rat Model of Metabolic Syndrome. ( Gao, HQ; Ji, XP; Li, CB; Li, XX; Wang, HW; Xiao, J; Zhang, C; Zhang, XY, 2015) |
| "It was found that AUC0-t, Cmax, Vd and CL of berberine and palmatine in metabolic syndrome rats were significantly different (P<0." | 3.80 | Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats. ( Jiao, Z; Li, ZD; Liu, QF; Shi, XJ; Wang, B; Zhong, MK, 2014) |
| "Berberine is a plant alkaloid possessing scientifically determined mechanisms of the prevention of the development of atherosclerosis, type 2 diabetes, and obesity, as well as cardiovascular complications and cancer." | 2.82 | Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. ( Nowak, R; Och, A; Och, M; Podgórska, D; Podgórski, R, 2022) |
| " While lifestyle approaches, such as with the Mediterranean diet, may prove to be too complex for the single patient, better knowledge of selected nutraceuticals and more appropriate formulations leading to improved bioavailability will certainly widen the use of these agents, already in large use for the management of these very frequent patient groups." | 2.55 | Nutraceutical approaches to metabolic syndrome. ( Calabresi, L; Pavanello, C; Ruscica, M; Sirtori, CR, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 8 (38.10) | 2.80 |
| Authors | Studies |
|---|---|
| Jamialahmadi, T | 1 |
| Guest, PC | 1 |
| Tasbandi, A | 1 |
| Al-Rasadi, K | 1 |
| Sahebkar, A | 1 |
| Chan, M | 1 |
| Qin, Z | 1 |
| Man, SC | 2 |
| Lam, M | 2 |
| Lai, WH | 2 |
| Ng, RMK | 1 |
| Lee, CK | 2 |
| Wong, TL | 1 |
| Lee, EHM | 1 |
| Wong, HK | 2 |
| Feng, Y | 1 |
| Liu, L | 1 |
| Han, F | 1 |
| Chen, EYH | 1 |
| Zhang, ZJ | 2 |
| Och, A | 1 |
| Och, M | 1 |
| Nowak, R | 1 |
| Podgórska, D | 1 |
| Podgórski, R | 1 |
| Lu, Y | 2 |
| Zhang, X | 1 |
| He, J | 1 |
| Dai, Z | 1 |
| Shi, P | 1 |
| Chang, F | 1 |
| Chan, MY | 1 |
| Qin, ZS | 1 |
| Ng, MKR | 1 |
| Chen, YHE | 1 |
| Lee, HME | 1 |
| Liu, LY | 1 |
| Ruiz-Herrera, VV | 1 |
| Navarro-Lara, SA | 1 |
| Andrade-Villanueva, JF | 1 |
| Alvarez-Zavala, M | 1 |
| Sánchez-Reyes, K | 1 |
| Toscano-Piña, M | 1 |
| Méndez-Clemente, AS | 1 |
| Martínez-Ayala, P | 1 |
| Valle-Rodríguez, A | 1 |
| González-Hernández, LA | 1 |
| Al-Naimi, MS | 1 |
| Rasheed, HA | 1 |
| Al-Kuraishy, HM | 1 |
| Al-Gareeb, AI | 1 |
| Shinjyo, N | 1 |
| Parkinson, J | 1 |
| Bell, J | 1 |
| Katsuno, T | 1 |
| Bligh, A | 1 |
| Zhang, SW | 1 |
| Zhou, J | 1 |
| Gober, HJ | 1 |
| Leung, WT | 1 |
| Wang, L | 1 |
| Sirtori, CR | 1 |
| Pavanello, C | 1 |
| Calabresi, L | 1 |
| Ruscica, M | 1 |
| Marchitto, N | 1 |
| Sindona, F | 1 |
| Fabrizio, A | 1 |
| Mauti, M | 1 |
| Andreozzi, S | 1 |
| Dalmaso, S | 1 |
| Raimondi, G | 1 |
| Galletti, F | 1 |
| Fazio, V | 1 |
| Gentile, M | 1 |
| Schillaci, G | 1 |
| Pucci, G | 1 |
| Battista, F | 1 |
| Mercurio, V | 2 |
| Bosso, G | 1 |
| Bonaduce, D | 1 |
| Brambilla, N | 1 |
| Vitalini, C | 1 |
| D'Amato, M | 1 |
| Giacovelli, G | 1 |
| Cicero, AF | 2 |
| Tartagni, E | 1 |
| Ertek, S | 1 |
| Pérez-Rubio, KG | 1 |
| González-Ortiz, M | 1 |
| Martínez-Abundis, E | 1 |
| Robles-Cervantes, JA | 1 |
| Espinel-Bermúdez, MC | 1 |
| Liu, QF | 1 |
| Shi, XJ | 1 |
| Li, ZD | 1 |
| Zhong, MK | 1 |
| Jiao, Z | 1 |
| Wang, B | 1 |
| Li, XX | 1 |
| Li, CB | 1 |
| Xiao, J | 1 |
| Gao, HQ | 1 |
| Wang, HW | 1 |
| Zhang, XY | 1 |
| Zhang, C | 1 |
| Ji, XP | 1 |
| Colletti, A | 1 |
| Yin, J | 1 |
| Zhang, H | 1 |
| Ye, J | 1 |
| Xia, X | 1 |
| Weng, J | 1 |
| Lamb, JJ | 1 |
| Holick, MF | 1 |
| Lerman, RH | 1 |
| Konda, VR | 1 |
| Minich, DM | 1 |
| Desai, A | 1 |
| Chen, TC | 1 |
| Austin, M | 1 |
| Kornberg, J | 1 |
| Chang, JL | 1 |
| Hsi, A | 1 |
| Bland, JS | 1 |
| Tripp, ML | 1 |
| Carlomagno, G | 1 |
| Pirozzi, C | 1 |
| Ruvolo, A | 1 |
| Fazio, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Amla Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion.[NCT03633630] | Phase 2/Phase 3 | 28 participants (Actual) | Interventional | 2019-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for berberine and Metabolic Syndrome
| Article | Year |
|---|---|
Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antineoplastic Agents; Antipsychotic Ag | 2022 |
The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials.
Topics: Berberine; Biomarkers; C-Reactive Protein; China; Cytokines; Humans; Inflammation; Metabolic Syndrom | 2022 |
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Berberine; Brain; Cholinergic Agonists; Cognitive Dysfunct | 2020 |
Effect and mechanism of berberine against polycystic ovary syndrome.
Topics: Animals; Berberine; Female; Humans; Insulin Resistance; Metabolic Syndrome; Polycystic Ovary Syndrom | 2021 |
Nutraceutical approaches to metabolic syndrome.
Topics: Berberine; Biological Products; Blood Glucose; Blood Pressure; Curcumin; Dietary Supplements; Female | 2017 |
Nutraceuticals for metabolic syndrome management: from laboratory to benchside.
Topics: Animals; Berberine; Body Weight; Cardiovascular Diseases; Cinnamomum zeylanicum; Dietary Supplements | 2014 |
Role of phytochemicals in the management of metabolic syndrome.
Topics: Acrolein; Berberine; Catechin; Cinnamates; Curcumin; Diet; Dietary Fiber; Dietary Supplements; Fatty | 2016 |
Traditional chinese medicine in treatment of metabolic syndrome.
Topics: Animals; Berberine; Diabetes Mellitus; Glucose; Humans; Hypoglycemic Agents; Hypolipidemic Agents; L | 2008 |
Targeting metabolic syndrome: candidate natural agents.
Topics: Animals; Anthocyanins; Berberine; China; Curcumin; Female; Flavanones; Genistein; Ginsenosides; Huma | 2010 |
6 trials available for berberine and Metabolic Syndrome
| Article | Year |
|---|---|
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial.
Topics: Antipsychotic Agents; Berberine; Double-Blind Method; Humans; Metabolic Syndrome; Schizophrenia; Wei | 2022 |
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection.
Topics: Adult; Berberine; Double-Blind Method; Female; HIV Infections; Humans; Insulin Resistance; Metabolic | 2023 |
Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial.
Topics: Adult; Aged; Berberine; Cholesterol, LDL; Dietary Supplements; Double-Blind Method; Fatty Alcohols; | 2019 |
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion.
Topics: Adult; Area Under Curve; Berberine; Blood Glucose; Blood Pressure; Cholesterol, HDL; Double-Blind Me | 2013 |
Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome.
Topics: Anti-Inflammatory Agents; Berberine; Biomarkers; Bone and Bones; Cholecalciferol; Collagen Type I; D | 2011 |
Effects of a nutraceutical combination on left ventricular remodeling and vasoreactivity in subjects with the metabolic syndrome.
Topics: Anticholesteremic Agents; Berberine; Cardiotonic Agents; Dietary Supplements; Fatty Alcohols; Female | 2012 |
6 other studies available for berberine and Metabolic Syndrome
| Article | Year |
|---|---|
Measuring the Effects of Berberine on Serum Prooxidant-Antioxidant Balance in Metabolic Syndrome.
Topics: Antioxidants; Berberine; Berberis; Humans; Metabolic Syndrome; Reactive Oxygen Species | 2022 |
Berberine for antipsychotic-induced metabolic syndrome in patients with schizophrenia spectrum disorders: abridged secondary publication.
Topics: Antipsychotic Agents; Berberine; Humans; Metabolic Syndrome; Schizophrenia | 2023 |
Berberine attenuates olanzapine induced-metabolic syndrome.
Topics: Animals; Berberine; Biomarkers; Insulin Resistance; Male; Metabolic Syndrome; Olanzapine; Prospectiv | 2019 |
Effect of new nutraceutical formulation with policosanol, berberine, red yeast rice, cassia nomame, astaxantine and Q10 coenzyme in patients with low-moderate dyslipidemia associated with intolerance to statins and metabolic syndrome.
Topics: Berberine; Biological Products; Cassia; Dietary Supplements; Dyslipidemias; Fatty Alcohols; Humans; | 2018 |
Pharmacokinetic comparisons of berberine and palmatine in normal and metabolic syndrome rats.
Topics: Administration, Oral; Animals; Area Under Curve; Berberine; Berberine Alkaloids; Drugs, Chinese Herb | 2014 |
Berberine Attenuates Vascular Remodeling and Inflammation in a Rat Model of Metabolic Syndrome.
Topics: Activating Transcription Factor 2; Animals; Aorta; Berberine; Disease Models, Animal; Inflammation; | 2015 |